biopharmadive.com
Lilly’s Omvoh approved by FDA for Crohn’s
An FDA approval means Omvoh is now an available biologic option for adults with Crohn’s disease, potentially expanding treatment choices. Payer decisions mentioned in the article could affect how quickly patients can access the drug without prior failures on other therapies.
Adults with Crohn’s disease or ulcerative colitis, patients considering or already on biologic therapy, gastroenterologists, and clinicians involved in IBD treatment and formulary decisions.
What To Know
Lilly’s Omvoh (an IL‑23–targeting biologic) received FDA approval for adults with Crohn’s disease; the drug was already approved for ulcerative colitis.
The article summarizes the approval basis (Phase 3 data showing benefit in patients with inadequate control on prior therapies), notes payer coverage positioning by some large pharmacy benefit managers, and places Omvoh in the competitive context with other IL‑23 drugs such as Skyrizi and Tremfaya.
The FDA cleared Omvoh for Crohn’s disease based on Phase 3 results and ongoing extension data reported by Lilly showing sustained benefit for many patients. The approval broadens the labeled use beyond the earlier ulcerative colitis indication (2023). Lilly and the article highlight the drug’s commercial potential but also note current modest sales to date.
Practical points: Some large pharmacy benefit managers have listed Omvoh as a first‑line therapy, which could affect how easy it is for patients to start the drug without trying other biologics first.
As with any newly approved medication, clinicians and patients should consult prescribing information and discuss risks, benefits, and insurance coverage when considering treatment. This summary is based on the published BiopharmaDive article and Lilly’s public statements; it does not provide medical advice.
The article is a regulatory/business news piece summarizing Lilly’s announcement and market context. The reported clinical benefits are described from Lilly’s Phase 3 and extension data; independent full study reports and prescribing information should be consulted for detailed efficacy and safety data. Coverage and cost will vary by insurer and region.
